NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis $34.94 +1.28 (+3.80%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$34.98 +0.04 (+0.10%) As of 07/17/2026 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pharvaris Stock (NASDAQ:PHVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharvaris alerts:Sign Up Key Stats Today's Range$33.24▼$35.0750-Day Range$28.81▼$35.9652-Week Range$19.12▼$36.60Volume236,448 shsAverage Volume548,634 shsMarket Capitalization$2.29 billionP/E RatioN/ADividend YieldN/APrice Target$50.08Consensus RatingModerate Buy Company Overview Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes. The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies. Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization. Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.AI Generated. May Contain Errors. Read More Pharvaris Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScorePHVS MarketRank™: Pharvaris scored higher than 85% of companies evaluated by MarketBeat, and ranked 78th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialPharvaris has a consensus price target of $50.08, representing about 43.3% upside from its current price of $34.94.Amount of Analyst CoveragePharvaris has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pharvaris' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pharvaris are expected to grow in the coming year, from ($3.20) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 7.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharvaris' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.71% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 2.27, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently decreased by 11.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.29 News SentimentPharvaris has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Pharvaris this week, compared to 4 articles on an average week.MarketBeat Follows5 people have added Pharvaris to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,746,065.00 in company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPharvaris has minimal institutional ownership at this time.Read more about Pharvaris' insider trading history. Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHVS Stock News HeadlinesPharvaris (NASDAQ:PHVS) Rating Lowered to "Sell" at Wall Street Zen1 hour ago | americanbankingnews.comHere's why Pharvaris NV (PHVS) is a great momentum stock to buyJuly 17 at 8:31 AM | msn.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Why this biotech, up 12% since its breakout, yo-yoed on a key FDA developmentJuly 6, 2026 | msn.comWhy this biotech, up 14% since its breakout, is on the rise once againJuly 6, 2026 | msn.comPharvaris (NASDAQ:PHVS) Director Sells $241,424.40 in StockJuly 2, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) Insider Peng Lu Sells 300 SharesJune 24, 2026 | insidertrades.comInsider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,291 Shares of StockJune 18, 2026 | insidertrades.comSee More Headlines PHVS Stock Analysis - Frequently Asked Questions How have PHVS shares performed this year? Pharvaris' stock was trading at $27.75 at the start of the year. Since then, PHVS shares have increased by 25.9% and is now trading at $34.94. How were Pharvaris' earnings last quarter? Pharvaris N.V. (NASDAQ:PHVS) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. When did Pharvaris IPO? Pharvaris (PHVS) raised $149 million in an IPO on Friday, February 5th 2021. The company issued 8,270,500 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. Who are Pharvaris' major shareholders? Top institutional shareholders of Pharvaris include CoreCap Advisors LLC. Insiders that own company stock include Johannes Gerardus Chri Schikan, Berndt Modig, David W Nassif, Peng Lu, Anne Lesage, Anne Lesage, Anna Nijdam, Wim Souverijns, Elisabeth Bjork, Robert Glassman and Viviane Monges. View institutional ownership trends. How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharvaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharvaris investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Disc Medicine (IRON) and Adobe (ADBE). Company Calendar Last Earnings5/12/2026Today7/17/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PHVS's financial health is in the Green zone, according to TradeSmith. PHVS has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHVS CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees30Year Founded2015Price Target and Rating Average Price Target for Pharvaris$50.08 High Price Target$74.00 Low Price Target$30.00 Potential Upside/Downside+43.3%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-67.56% Return on Assets-61.13% Debt Debt-to-Equity RatioN/A Current Ratio11.24 Quick Ratio11.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book7.42Miscellaneous Outstanding Shares65,410,000Free Float57,664,000Market Cap$2.29 billion OptionableNot Optionable Beta-2.34 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:PHVS) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored3 AI stocks to buy before August 2026Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredURGENT Dollar Reset Warning for MondayA 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...Golden Portfolio | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
